Company Filing History:
Years Active: 2006
Title: Catherine Régnier: Innovator in Biopharmaceuticals
Introduction
Catherine Régnier is a prominent inventor based in South San Francisco, CA. She has made significant contributions to the field of biopharmaceuticals, particularly through her innovative work on IKK-α proteins and related nucleic acids. Her research has the potential to impact diagnosis and therapy in various medical applications.
Latest Patents
Catherine holds a patent for her invention titled "IKK-α proteins, nucleic acids and methods." This invention provides methods and compositions related to IκB kinase, IKK-α, and associated nucleic acids. The polypeptides can be produced recombinantly from transformed host cells or purified from human cells. The invention also includes isolated IKK-α hybridization probes and primers that can specifically hybridize with the disclosed IKK-α genes, as well as IKK-α-specific binding agents such as specific antibodies. These compositions are valuable in diagnosis, therapy, and the biopharmaceutical industry.
Career Highlights
Catherine has established herself as a key figure in her field, working at Amgen Inc., a leading biopharmaceutical company. Her expertise and innovative approach have contributed to advancements in therapeutic methods and compositions.
Collaborations
Catherine collaborates with talented professionals in her field, including her coworkers Mike Rothe and Zhaodan Cao. Their combined efforts enhance the research and development of biopharmaceutical innovations.
Conclusion
Catherine Régnier's work exemplifies the impact of innovation in the biopharmaceutical industry. Her contributions through her patent on IKK-α proteins and nucleic acids highlight her role as a leading inventor in this vital field.